The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1643
ISSUE1643
February 7, 2022
Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
February 7, 2022 (Issue: 1643)
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for
once-weekly subcutaneous (SC) treatment of growth
failure due to inadequate secretion of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.